

## Internal tremors and vibrations in long COVID: a cross-sectional study

Tianna Zhou<sup>1</sup>; Lindsay McAlpine<sup>2</sup>; Teresa Michelsen<sup>3</sup>; César Caraballo<sup>4</sup>; Mitsuaki Sawano<sup>4</sup>;  
Bornali Bhattacharjee<sup>5,6</sup>; Yuan Lu<sup>4,7</sup>; Akiko Iwasaki<sup>5,6,8</sup>; Harlan M. Krumholz<sup>4,6,7,9\*</sup>

1. Yale School of Medicine, New Haven, CT, USA

2. Department of Neurology, Yale School of Medicine, New Haven, CT, USA

3. Avocet Consulting LLC, Hoodspout, WA, USA

4. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT,  
USA

5. Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA

6. Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA

7. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of  
Medicine, New Haven, CT, USA

8. Howard Hughes Medical Institute, Chevy Chase, MD, USA

9. Department of Health Policy and Management, Yale School of Public Health, New Haven,  
CT, USA

\* Corresponding author

Email: [harlan.krumholz@yale.edu](mailto:harlan.krumholz@yale.edu) (HMK)

21 **ABSTRACT**

22 **Background:** Internal tremors and vibrations symptoms have been described as part of  
23 neurologic disorders but have not been fully described as a part of long COVID. We compared  
24 demographics, socioeconomic characteristics, pre-pandemic comorbidities, and new-onset  
25 conditions between people with internal tremors and vibrations as part of their long COVID  
26 symptoms and people with long COVID but without these symptoms.

27 **Methods:** A cross-sectional study, Listen to Immune, Symptom and Treatment Experiences Now  
28 (LISTEN), collected data from adults with long COVID. The study sample included 423  
29 participants enrolled between May 2022 and June 2023.

30 **Results:** The 423 participants had a median age of 46 years (interquartile range, 38-56), 74%  
31 were female, 87% were Non-Hispanic White, and 158 (37%) reported “internal tremors, or  
32 buzzing/vibration” as a long COVID symptom. Before long COVID, the groups had similar  
33 comorbidities. Post-COVID, participants with internal tremors and vibrations had significantly  
34 worse health as measured by the Euro-QoL visual analogue scale (median: 40 vs. 50 points,  $P =$   
35  $0.007$ ), higher rates of financial difficulties caused by the pandemic and housing insecurity ( $P <$   
36  $0.001$  for each), and were significantly more likely to have new-onset conditions of mast cell  
37 disorders (11% vs. 2.6%), neurologic conditions (22% vs. 8.3%), anxiety (20% vs. 8.7%), and  
38 trauma- or stress-related mental health disorders (12% vs. 3.4%) compared with those without  
39 internal tremors (Bonferroni-adjusted  $P < 0.05$  for each). Participants with internal tremors also  
40 reported significantly higher rates of cardiovascular, gastrointestinal, integumentary, and  
41 neurologic long COVID symptoms compared with those without internal tremors (Bonferroni-  
42 adjusted  $P < 0.05$  for each).

43 **Conclusions and Relevance:** Among people with long COVID, those with internal tremors and  
44 vibrations have more associated symptoms and worse health status, suggesting it may be  
45 associated with a severe phenotype of the condition.

## 46 INTRODUCTION

47 Internal tremors and vibrations are an understudied symptom, despite their first written  
48 descriptions by a patient in the 1800s.<sup>1</sup> Internal tremors were described as a movement or  
49 sensation of movement at any location inside the body. They can occur either with or without  
50 visible external movement or muscle spasms.<sup>2,3</sup> Until recently, internal tremors have been  
51 described mostly among patients with Parkinson's disease and essential tremor.<sup>1-6</sup> In those  
52 populations, internal tremors have been associated with anxiety and sensory abnormalities such  
53 as aching, tingling, and burning.<sup>5</sup> In a recent qualitative study, we described long COVID  
54 symptoms of internal tremors and vibrations and their substantial and negative impact on  
55 people's quality of life.<sup>2</sup>

56 Here, we compared the demographics, socioeconomic characteristics, pre-pandemic  
57 comorbidities, and new-onset conditions between people with long COVID symptoms of internal  
58 tremors and vibrations and others with long COVID. To the best of our knowledge, to date, no  
59 quantitative study has described long COVID symptoms of internal tremors and vibrations.  
60 Throughout this paper, terminology and definitions were deliberately chosen to respect  
61 participants' epistemic authority. For example, long COVID was defined by participants' self-  
62 report rather than definitions proposed by public health and medical organizations.<sup>7</sup> Similarly,  
63 this paper used the term "internal tremors," a shortened phrase to denote "internal tremors and  
64 vibrations," which reflects the language used by participants to describe their symptom  
65 experience. Internal tremors were considered to be different from tremors, which were defined  
66 by expert consensus as "involuntary, rhythmic, oscillatory movement of a body part."<sup>8</sup> In this  
67 paper's context, internal tremors were considered a participant-reported symptom rather than a  
68 clinician-observed sign.<sup>9</sup>

69

**70 METHODS****71 Study design**

72 We used data from the long COVID component of the Listen to Immune, Symptom, and  
73 Treatment Experiences Now (LISTEN) Study, an online, decentralized, participant-centric,  
74 observational study of adults interested in contributing to COVID-related research. The LISTEN  
75 Study included two parts: survey and electronic health record data collection and analysis to  
76 characterize clinical phenotypes and biospecimen collection for immunophenotyping. This study  
77 focused on survey data only.

**78 Study sample**

79 LISTEN recruited from people who joined Hugo Health Kindred, an online platform of  
80 individuals 18 years and older who were interested in contributing to COVID-related research.  
81 The objective was to include people with long COVID, vaccine-associated adverse events, and  
82 those who could act as controls; this study focused on people with long COVID. People joined  
83 Hugo Health Kindred by word of mouth, including via social media. Additionally, a subset of  
84 active Kindred members was invited to join a Kindred Advisory Task Force to help recruit others  
85 by sharing information about Kindred. Eligibility criteria to join LISTEN were 1) age 18 years or  
86 older and 2) English speaking.

**87 Data collection**

88 Those who joined Kindred were offered a series of surveys developed in an iterative  
89 process that included input from people with long COVID and those with vaccine-associated  
90 adverse events. Surveys were available for completion online on computers or mobile devices.  
91 Participants were sent electronic reminders to encourage survey completion. The data became

92 part of each person’s data repository, available to be shared with research studies. People in  
93 Kindred were offered the opportunity to join LISTEN; e-consent was performed online.

94 This study was restricted to people who joined LISTEN and had completed their  
95 demographic and conditions and symptoms surveys. Participants with long COVID were  
96 identified as those who replied “yes” to the question, “Do you think you have long COVID?”

97 Demographic and socioeconomic survey items included age, gender, race and ethnicity,  
98 marital status, pre-pandemic employment and income, housing insecurity, and country of  
99 residence. Self-reported time of index SARS-CoV-2 infection was categorized as Pre-Delta  
100 (before 26 June 2021), Delta (26 June 2021–24 December 2021), Omicron (25 December 2021–  
101 25 June 2022), and Post-Omicron (after 25 June 2022), consistent with time period definitions  
102 associated with dominant variants of SARS-CoV-2.<sup>10</sup> SARS-CoV-2 infection severity was  
103 assessed by self-reported hospitalization history for COVID-related conditions.

104 The demographic survey included two questions about health status; self-reported health  
105 status was assessed by the Euro-QoL visual analogue scale (EQ-VAS), and the question, “We are  
106 trying to get a sense of how bad your long COVID symptoms are when you feel them the most.  
107 On the slider below, with 0 being a trivial illness and 100 being unbearable, please let us know  
108 what the worst days are like.” (S1 Methods - Health status questions).<sup>11</sup>

109 The conditions and symptoms survey assessed pre-pandemic comorbidities, current  
110 conditions, and long COVID symptoms. Pre-pandemic comorbidities were assessed using the  
111 question, “Have you ever been told by a doctor before January 2020 that you have any of the  
112 following?” followed by a list of 30 medical diagnostic categories, 8 psychiatric diagnostic  
113 categories, “other,” and “none of the above” (S2 Methods – Pre-pandemic comorbidities  
114 questions). Current conditions were assessed using the question, “Currently, have you ever been

115 told by a doctor that you have any of the following?” followed by a list of 31 medical diagnostic  
116 categories, 8 psychiatric diagnostic categories, “other,” and “none of the above” (S2 Methods -  
117 Current conditions questions). For each participant, we defined new-onset conditions as those  
118 reported as a current condition but not reported as a pre-pandemic comorbidity.

119 Long COVID symptoms were assessed by the question, “Please select all following  
120 health conditions that you have had as a result of long COVID,” followed by a list of 95 specific  
121 symptoms, “other,” and “none of the above” (S3 Methods - Long COVID symptoms questions).  
122 All phrasings of symptoms on the multiple-choice list were created in collaboration with  
123 participants and were reported in this study’s tables as they appeared on the survey. We excluded  
124 the fatigue symptom and runny nose symptom variables from analysis due to their overlap with  
125 the excessive fatigue symptom and congested or runny nose symptom.

126 After exclusion for incomplete conditions and symptoms surveys, the study sample  
127 represented 69% of participants enrolled in LISTEN who completed the demographic survey and  
128 reported long COVID and no vaccine-associated adverse events.

### 129 Statistical analysis

130 We described participant characteristics using percentages for categorical variables, and  
131 median and interquartile range (IQR) for continuous variables. We compared participants with  
132 and without internal tremors on their demographic and socioeconomic characteristics, medical  
133 conditions, and long COVID symptoms. We used chi-squared tests and Fisher’s exact tests to  
134 compare responses for categorical variables and Wilcoxon rank-sum tests and Kruskal-Wallis  
135 rank-sum tests for continuous variables. When comparing the three domains of pre-pandemic  
136 comorbidities, new-onset conditions, and long COVID symptoms between the two groups, we  
137 corrected for multiple testing using the Bonferroni method within each domain and reported

138 adjusted P-values. All tests were two-sided.  $P < 0.05$  was considered statistically significant. By  
139 using the Bonferroni method, family-wise error rates were controlled at the level of 0.05. All  
140 statistical analyses were done in R version 4.2.3 (2023-03-15).

#### 141 Ethical considerations

142 The LISTEN study was approved by the Yale University Institutional Review Board on  
143 April 1, 2022. Participants were provided electronic written consent forms. LISTEN conforms to  
144 the Declaration of Helsinki and STROBE reporting guidelines.

145

## 146 **RESULTS**

147 From 7 May 2022 to 1 June 2023, 614 people with long COVID consented to and  
148 enrolled in LISTEN and completed the demographic survey (Figure 1). Among them, 191  
149 participants (31%) were excluded due to incomplete conditions and symptoms surveys, leaving  
150 423 participants (69%) in the study population (Figure 1). The included participants were  
151 significantly older (median: 46 years vs. 43 years,  $P = 0.014$ ) compared with those who were  
152 excluded from the analysis (S1 Table). The participants were similar in gender, race and  
153 ethnicity, country of residence, and EQ-VAS health status.

#### 154 Demographic and pre-pandemic socioeconomic characteristics

155 Among participants with long COVID, median age was 46 years (IQR, 38-56), 74% were  
156 female, 87% were Non-Hispanic White, and 158 participants (37%) reported internal tremors  
157 (Table 1). Compared with participants without internal tremors, those with internal tremors were  
158 more likely to be female (81% vs. 70%,  $P = 0.018$ ). The two groups had no significant  
159 differences in age, race and ethnicity, marital status, pre-pandemic employment status, and pre-  
160 pandemic household income ( $P > 0.05$ ).



161 Pre-pandemic comorbidities

162 Overall, among participants, the most common self-reported pre-pandemic comorbidities  
163 were anxiety disorders (30%), depressive disorders (29%), and gastrointestinal issues, including  
164 irritable bowel syndrome and acid reflux (24%). After adjusting for multiple testing, participants  
165 with and without internal tremors were not significantly different in any self-reported pre-  
166 pandemic comorbidities (adjusted  $P > 0.05$  for each; S2 Table).

167 SARS-CoV-2 infection characteristics and post-COVID socioeconomic characteristics

168 Overall, the most common period for index SARS-CoV-2 infection was during the Pre-  
169 Delta wave (46%) and 9.5% of participants were hospitalized due to COVID-related conditions  
170 (Table 2, S1 Figure). Participants with internal tremors were significantly more likely to report  
171 their index infection during the Pre-Delta wave (53% vs. 42%,  $P = 0.006$ ) but were not  
172 significantly different in hospitalization rates due to COVID-related conditions. Participants with  
173 internal tremors had a significantly longer duration between their initial infections and the date of  
174 completing LISTEN's symptom survey (median: 74 weeks vs. 54 weeks,  $P = 0.003$ ).

175 Participants with and without internal tremors had no significant differences in their  
176 health insurance status and level of social support when completing the surveys ( $P > 0.05$ ; Table  
177 2). Participants with internal tremors were significantly more likely to report having financial  
178 difficulties caused by the pandemic (very much financial difficulties, 22% vs. 11%,  $P < 0.001$ ),  
179 often feeling socially isolated (43% vs. 37%,  $P = 0.039$ ), and housing insecurity (worried about  
180 losing housing, 18% vs. 8.3%,  $P < 0.001$ ).

181 Health status

182 Participants with internal tremors reported significantly worse health as measured by EQ-  
183 VAS, using a visual sliding scale ranging from 0 to 100, where 0 means the worst and 100 means

184 the best (median: 40 points [IQR, 30-60] vs. 50 points [IQR, 35-62],  $P = 0.007$ ) compared with  
185 those with no internal tremors (Table 3, Figure 2). When asked to rate their symptom severity on  
186 their worst days using a visual sliding scale ranging from 0 to 100, with 0 being a trivial illness  
187 and 100 being unbearable, participants with internal tremors reported greater symptom severity  
188 compared with those with no internal tremors (median: 80 points [IQR 73–90] vs. 73 points  
189 [IQR, 60–82], respectively,  $P < 0.001$ ; Table 3, Figure 3). In both groups, the time period of the  
190 index SARS-CoV-2 infection was not significantly associated with EQ-VAS scores (S3 Table).

#### 191 New-onset conditions

192 Overall, the most common new-onset conditions among all participants were postural  
193 orthostatic tachycardia syndrome or other dysautonomia (25%), gastrointestinal issues (15%),  
194 and neurologic conditions (13%) (S4 Table). Compared with participants without internal  
195 tremors, significantly greater proportions of participants with internal tremors reported new-  
196 onset mast cell disorders (11% vs. 2.6%, adjusted  $P = 0.008$ ), neurologic conditions (22% vs.  
197 8.3%, adjusted  $P = 0.004$ ), anxiety disorders (20% vs. 8.7%, adjusted  $P = 0.038$ ), and trauma-  
198 and stressor-related disorders (12% vs. 3.4%, adjusted  $P = 0.019$ ; Figure 2, S4 Table).

#### 199 Long COVID symptoms

200 Overall, the most common long COVID symptoms reported were excessive fatigue  
201 (87%), brain fog (86%), exercise intolerance (79%), trouble falling or staying asleep (72%), and  
202 memory problems (70%) (S5 Table). Among participants with internal tremors, the most  
203 common symptoms appeared to affect constitutional, neurological, and cardiovascular systems.

204 For constitutional and generalized symptoms, from most common to least common,  
205 participants with internal tremors had significantly higher rates of trouble falling or staying  
206 asleep (84% vs. 65%), dizziness (75% vs. 49%), muscle or body aches (70% vs. 49%), heat

207 intolerance (61% vs. 38%), night sweats (54% vs. 34%), chills but no fever (49% vs. 26%),  
208 constant thirst (41% vs. 17%), feelings of impending doom (35% vs. 19%), nightmares (26% vs.  
209 12%), abnormally low temperature (22% vs. 7.5%), and fainting (19% vs. 4.9%) compared with  
210 those without internal tremors (adjusted  $P < 0.05$  for each; S5 Table). Rates of exercise  
211 intolerance and excessive fatigue did not differ significantly between the two groups (adjusted  
212  $P > 0.05$  for each).

213 For neurological symptoms, from most common to least common, participants with  
214 internal tremors were more likely to have headaches (77% vs. 56%), tingling, pins and needles,  
215 or numbness (72% vs. 41%), tremors or shakiness (65% vs. 22%), neuropathy (nerve sensations  
216 including pain) anywhere in the body (64% vs. 34%), pressure at the base of the head (51% vs.  
217 27%), burning sensations (42% vs. 19%), migraines (42% vs. 23%), and painful scalp (25% vs.  
218 8.7%) compared with those with no internal tremors (adjusted  $P < 0.05$  for each; S5 Table).  
219 Participants with internal tremors were also more likely to have auditory, visual, and olfactory  
220 symptoms such as tinnitus (62% vs. 36%), loss or decrease in quality of vision/blurry vision  
221 (54% vs. 34%), floaters or flashes of light in vision (47% vs. 16%), changed sense of smell (42%  
222 vs. 25%), and phantom smells (35% vs. 16%) compared with those without internal tremors  
223 (adjusted  $P < 0.05$  for each). The two groups were not significantly different in rates of  
224 confusion, brain fog, memory problems, difficulty speaking, seizures, loss of hearing, and  
225 gustatory symptoms (adjusted  $P > 0.05$  for each).

226 For cardiovascular and thoracic symptoms, from most common to least common,  
227 participants with internal tremors were more likely to have palpitations (66% vs. 44%),  
228 tachycardia after standing up (58% vs. 39%) or at rest (57% vs. 34%), sharp or sudden chest pain  
229 (47% vs. 22%), persistent chest pain or pressure (44% vs. 26%), costochondritis (37% vs. 18%),

230 and bilateral neck throbbing (23% vs. 7.5%) compared with those without internal tremors  
231 (adjusted  $P < 0.05$  for each; S5 Table). The two groups were not significantly different in rates of  
232 pulmonary symptoms such as cough, wheezing, and shortness of breath (adjusted  $P > 0.05$  for  
233 each).

234 Participants with internal tremors were more likely to have integumentary symptoms  
235 such as hair loss (56% vs. 30%), itchiness (39% vs. 17%), skin bruising (32% vs. 16%), change  
236 in nails (30% vs. 13%), discoloration of the skin (29% vs. 11%), cracked or dry lips (28% vs.  
237 13%), tender or itchy rash or chilblains on the toes or foot (15% vs. 1.9%), and chilblains on the  
238 hands or feet (11% vs. 2.3%) compared with those with no internal tremors (adjusted  $P < 0.05$   
239 for each; S5 Table).

240 For gastrointestinal symptoms, participants with internal tremors were more likely to  
241 have abdominal pain (47% vs. 23%), diarrhea (43% vs. 24%), loss of appetite (41% vs. 24%),  
242 throat pain or discomfort (34% vs. 16%), inability to eat or tolerate food (32% vs. 15%),  
243 difficulty swallowing (27% vs. 12%), and lump in throat (22% vs. 9.1%) compared with those  
244 with no internal tremors (adjusted  $P < 0.05$  for all; S5 Table). The two groups were not  
245 significantly different in rates of other gastrointestinal symptoms such as acid reflux/heartburn,  
246 constipation, and nausea/vomiting (adjusted  $P > 0.05$  for each).

247

## 248 **DISCUSSION**

249 In a cross-sectional sample of people with long COVID, we found internal tremors were  
250 a common symptom, affecting 37% of participants. Participants with internal tremors were like  
251 those without internal tremors in their demographic characteristics. Importantly, although the  
252 two groups had similar pre-pandemic comorbidities, participants with internal tremors had worse

253 EQ-VAS health status and higher rates of financial difficulties caused by the pandemic and  
254 housing insecurity compared with those without internal tremors. Participants with internal  
255 tremors reported significantly higher rates of new-onset conditions for mast cell disorders,  
256 neurologic disorders, anxiety disorders, and trauma- and stress-related disorders. Participants  
257 with internal tremors also reported significantly higher rates of cardiovascular, neurologic,  
258 gastrointestinal, and integumentary long COVID symptoms.

259 To the best of our knowledge, only four prior studies have described patients with  
260 internal tremors,<sup>3-5, 12</sup> no quantitative study of patients with long COVID has fully described  
261 symptoms of internal tremors. A prior study of patients with Parkinson's disease found that  
262 internal tremors were associated with anxiety and sensory symptoms such as aching, tingling,  
263 and burning.<sup>5</sup> Sensory abnormalities have also been described in long COVID cohorts,<sup>13</sup> as well  
264 as in the subset of people with post-COVID onset of neuropathies<sup>14</sup>, such as small fiber  
265 neuropathy.<sup>15, 16</sup> These prior long COVID studies described sensory symptoms such as burning,  
266 tingling, and numbness, but did not explicitly describe internal tremors and vibrations. Two  
267 recent studies based on large prospective cohorts of people with long COVID did not report on  
268 symptoms of internal tremors.<sup>10, 17</sup> Our study adds to prior findings by showing that compared  
269 with others with long COVID, participants with internal tremors had significantly higher rates of  
270 sensory abnormalities such as neuropathy sensations, olfactory changes, and tinnitus.

271 Prior studies also noted associations among dysautonomia, long COVID, and small fiber  
272 neuropathy.<sup>16, 18</sup> Compared with participants with no internal tremors, those with internal tremors  
273 reported significantly higher rates of symptoms across multiple autonomic domains, including  
274 orthostatic symptoms (tachycardia, dizziness, fainting, and weakened neck, which may resemble  
275 coat hanger syndrome<sup>19</sup>), vasomotor symptoms (skin discoloration), secretomotor (night sweats,

276 dry eyes), and symptoms related to slow or fast gastrointestinal transit (difficulty swallowing,  
277 diarrhea).<sup>19-21</sup> Rates of new-onset dysautonomia were higher among participants with internal  
278 tremors, with statistical significance before but not after Bonferroni correction. The mechanism  
279 of dysautonomia among patients with Parkinson's disease may be related to organ-selective  
280 sympathetic denervation,<sup>22</sup> but the pathophysiologic links among dysautonomia, long COVID,  
281 and internal tremors have not been established and should be explored in further studies.

282 In this study, participants with internal tremors had new-onset mast cell disorders at a  
283 significantly higher rate compared with participants with long COVID but no internal tremors.  
284 Mast cells form neuroimmune synapses with peripheral nerves and serve both an afferent role to  
285 modulate neural function, as well as an efferent role in neurogenic inflammation.<sup>23</sup> Mast cell  
286 activation symptoms have been documented among long COVID patients<sup>24</sup> and patients with  
287 small fiber neuropathy.<sup>25</sup> Further studies will be needed to elucidate the underlying  
288 pathophysiologic link and determine if any subset of long COVID conditions and mast cell  
289 disorders are causally related.

290 Our findings add nuance to the hypothesized associations between myalgic  
291 encephalomyelitis/chronic fatigue syndrome and long COVID, which are often discussed  
292 together due to overlapping symptomatology and infectious etiopathogenesis.<sup>26-28</sup> Although  
293 greater than 70% of all subgroups in this study reported excessive fatigue and exercise  
294 intolerance, these hallmark symptoms of myalgic encephalomyelitis/chronic fatigue syndrome  
295 were not significantly associated with internal tremors. Our findings are consistent with prior  
296 observations of long COVID as a heterogeneous condition with many phenotypes,<sup>29</sup> which may  
297 be driven by several mechanisms.<sup>30</sup>

298 Study limitations

299           This study has several limitations. The study sample was recruited from an online long  
300 COVID community and should not be considered representative. Rather, the study provides an  
301 opportunity to describe the characteristics of people within the online community who do and do  
302 not have internal tremors and vibrations. In this study, 31% of enrolled participants with long  
303 COVID did not complete their conditions and symptoms surveys. The effort required to  
304 complete surveys may preclude those with low functional status from participation. However,  
305 participants included and excluded based on symptom survey completion were similar in their  
306 low median EQ-VAS score. In addition, conditions and symptoms are based on self-reporting  
307 using a pre-specified checklist, which may be susceptible to recall bias with unclear  
308 directionality for under versus overreporting, as well as inaccuracies such as misdiagnoses due to  
309 uncertainties surrounding long COVID evaluation and management during early stages of the  
310 pandemic.

### 311 Conclusions

312           Internal tremors and vibrations are common symptoms among people with long COVID.  
313 People with these symptoms had pre-infection characteristics similar to those of others with long  
314 COVID, but compared with others who had long COVID, they had worse EQ-VAS health status  
315 and higher rates of financial difficulties and housing insecurity, and higher self-reported rates of  
316 new-onset conditions of mast cell disorders, neurologic conditions, anxiety, and trauma- and  
317 stressor-related conditions. Individuals with long COVID symptoms of internal tremors may  
318 experience a particularly severe phenotype of long COVID. Clinicians should be aware of  
319 internal tremors and vibrations as a long COVID symptom. Further research is needed to clarify  
320 the pathophysiology of internal tremors and vibrations and identify potential treatment targets.

321 **ACKNOWLEDGMENTS**

322 We thank Shaun Barcavage, FNP-BC, James Curry, MD, and Kelley Royer, RN for their  
323 feedback and for sharing their lived experiences with the writing team, and Maria Johnson for  
324 her editorial contributions.

325

326 **FUNDING**

327 This study was in part funded by the Howard Hughes Medical Institute Collaborative COVID-19  
328 Initiative, and grants from the National Institute of Allergy and Infectious Diseases  
329 (R01AI157488 to Akiko Iwasaki).

330

331 **CONFLICTS OF INTEREST**

332 Harlan Krumholz and his spouse are co-founders of, and have equity in, Hugo Health, the  
333 personalized health data-platform company that developed the Hugo Kindred platform. Dr.  
334 Krumholz is a scientific advisor to, and his spouse is an officer with, Hugo Health. His  
335 involvement in this study is overseen by the Yale Conflict of Interest Committee. In the past  
336 three years, Harlan Krumholz received expenses and/or personal fees from UnitedHealth,  
337 Element Science, Eyedentifeye, and F-Prime. He is a co-founder of Refactor Health and is  
338 associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare &  
339 Medicaid Services and through Yale University from the Food and Drug Administration,  
340 Johnson & Johnson, Google, and Pfizer.



## 341 REFERENCES


- 342 1. Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von  
343 Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a  
344 patient. *Neurology*. Mar 1995;45(3 Pt 1):565-8. doi:10.1212/wnl.45.3.565
- 345 2. Massey D, Baker AD, Berrent DZ, et al. Internal tremors and vibration symptoms among  
346 people with post-acute sequelae of SARS-CoV-2: a narrative review of patient reports. *medRxiv*.  
347 2021:2021.12.03.21267146. doi:10.1101/2021.12.03.21267146
- 348 3. Cochrane GD, Rizvi S, Abrantes A, Crabtree B, Cahill J, Friedman JH. Internal tremor in  
349 Parkinson's disease, multiple sclerosis, and essential tremor. *Parkinsonism Relat Disord*. Oct  
350 2015;21(10):1145-7. doi:10.1016/j.parkreldis.2015.07.014
- 351 4. Raudino F. Non motor off in Parkinson's disease. *Acta Neurol Scand*. Nov  
352 2001;104(5):312-5. doi:10.1034/j.1600-0404.2001.00357.x
- 353 5. Shulman LM, Singer C, Bean JA, Weiner WJ. Internal tremor in patients with  
354 Parkinson's disease. *Mov Disord*. Jan 1996;11(1):3-7. doi:10.1002/mds.870110103
- 355 6. Friedman JH. Non-motor movement disorders: internal tremor. *Med Health R I*. Aug  
356 2009;92(8):262.
- 357 7. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition  
358 Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19  
359 condition by a Delphi consensus. *Lancet Infect Dis*. Apr 2022;22(4):e102-e107.  
360 doi:10.1016/S1473-3099(21)00703-9
- 361 8. Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors.  
362 from the task force on tremor of the International Parkinson and Movement Disorder Society.  
363 *Mov Disord*. Jan 2018;33(1):75-87. doi:10.1002/mds.27121
- 364 9. Louis ED, Bain PG. Problems and controversies in tremor classification. *J Neurol Sci*.  
365 Apr 15 2022;435:120204. doi:10.1016/j.jns.2022.120204
- 366 10. Gottlieb M, Wang R, Yu H, et al. Severe fatigue and persistent symptoms at three months  
367 following SARS-CoV-2 infections during the Pre-Delta, Delta, and Omicron time periods: a  
368 multicenter prospective cohort study. *Clin Infect Dis*. Jan 27 2023;doi:10.1093/cid/ciad045
- 369 11. Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group.  
370 *Annals of Medicine*. 2001/01/01 2001;33(5):337-343. doi:10.3109/07853890109002087
- 371 12. Borromei A, Caramelli R, Battistelli P, D'Orsi U, Pasini W, Vargiu B. 5-30-01 Internal  
372 tremor: a clinical marker for the onset of Parkinson's disease? *Journal of the Neurological  
373 Sciences*. Sep 1997;150:S315. doi:10.1016/S0022-510X(97)86438-6
- 374 13. Writing Committee for the COMEBAC Study Group, Morin L, Savale L, et al. Four-  
375 Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA*. Apr  
376 20 2021;325(15):1525-1534. doi:10.1001/jama.2021.3331
- 377 14. Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations of patients  
378 with prolonged long COVID. *Neurol Neuroimmunol Neuroinflamm*. May  
379 2022;9(3)doi:10.1212/NXI.0000000000001146
- 380 15. Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L, Shin SC. Small fiber neuropathy  
381 associated with SARS-CoV-2 infection. *Muscle Nerve*. Apr 2022;65(4):440-443.  
382 doi:10.1002/mus.27458
- 383 16. Novak P, Giannetti MP, Weller E, et al. Network autonomic analysis of post-acute  
384 sequelae of COVID-19 and postural tachycardia syndrome. *Neurol Sci*. Dec 2022;43(12):6627-  
385 6638. doi:10.1007/s10072-022-06423-y

- 386 17. Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute  
387 Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023;329(22):1934-1946.  
388 doi:10.1001/jama.2023.8823
- 389 18. Shoenfeld Y, Ryabkova VA, Scheibenbogen C, et al. Complex syndromes of chronic  
390 pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber  
391 neuropathy. *Clin Immunol*. May 2020;214:108384. doi:10.1016/j.clim.2020.108384
- 392 19. Goldstein DS, Cheshire WP, Jr. The autonomic medical history. *Clin Auton Res*. Aug  
393 2017;27(4):223-233. doi:10.1007/s10286-017-0425-7
- 394 20. Kim MJ, Farrell J. Orthostatic hypotension: a practical approach. *Am Fam Physician*. Jan  
395 1 2022;105(1):39-49.
- 396 21. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and  
397 abbreviated Composite Autonomic Symptom Score. *Mayo Clin Proc*. Dec 2012;87(12):1196-  
398 201. doi:10.1016/j.mayocp.2012.10.013
- 399 22. Goldstein DS. Dysautonomia in Parkinson disease. *Compr Physiol*. Apr 2014;4(2):805-  
400 26. doi:10.1002/cphy.c130026
- 401 23. Forsythe P. Mast cells in neuroimmune interactions. *Trends Neurosci*. Jan 2019;42(1):43-  
402 55. doi:10.1016/j.tins.2018.09.006
- 403 24. Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell  
404 activation symptoms are prevalent in Long-COVID. *Int J Infect Dis*. Nov 2021;112:217-226.  
405 doi:10.1016/j.ijid.2021.09.043
- 406 25. Novak P, Giannetti MP, Weller E, Hamilton MJ, Castells M. Mast cell disorders are  
407 associated with decreased cerebral blood flow and small fiber neuropathy. *Ann Allergy Asthma*  
408 *Immunol*. Mar 2022;128(3):299-306 e1. doi:10.1016/j.anai.2021.10.006
- 409 26. Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue  
410 syndrome (ME/CFS)-a Systemic review and comparison of clinical presentation and  
411 symptomatology. *Medicina (Kaunas)*. Apr 26 2021;57(5)doi:10.3390/medicina57050418
- 412 27. Retornaz F, Rebaudet S, Stavris C, Jammes Y. Long-term neuromuscular consequences  
413 of SARS-Cov-2 and their similarities with myalgic encephalomyelitis/chronic fatigue syndrome:  
414 results of the retrospective CoLGEM study. *J Transl Med*. Sep 24 2022;20(1):429.  
415 doi:10.1186/s12967-022-03638-7
- 416 28. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes.  
417 *Nat Med*. May 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
- 418 29. Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2  
419 infection subphenotypes. *Nat Med*. Jan 2023;29(1):226-235. doi:10.1038/s41591-022-02116-3
- 420 30. Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long  
421 COVID: a comprehensive review. *Ann Med*. Dec 2022;54(1):1473-1487.  
422 doi:10.1080/07853890.2022.2076901
- 423

424

425 **TABLES AND FIGURES**

426 Figure 1. Sample selection




427

428 LISTEN, Listen to Immune, Symptom and Treatment Experiences Now

429


430

431 Figure 2. Distribution of health status, measured by the Euro-QoL visual analogue scale



432 Assessed by the question, “Please choose one point in this 0-100 scale, which can best represent  
433 your health today (0 means the worst and 100 means the best).” (S1 Methods - Health status  
434 questions)  
435  
436


437 Figure 3. Distribution of symptom severity



438  
 439 Assessed by the question, “We are trying to get a sense of how bad your long COVID symptoms  
 440 are when you feel them the most. On the slider below, with 0 being a trivial illness and 100 being  
 441 unbearable, please let us know what the worst days are like.” (S1 Methods - Health status  
 442 questions)

443  
 444

445 Figure 4. New-onset conditions



446

447

448 \* Bonferroni adjusted  $p < 0.05$ 449 \*\* Bonferroni adjusted  $p < 0.01$ 

450

451 Abbreviations: MCAS, mast cell activation syndrome; ME/CFS, myalgic

452 encephalomyelitis/chronic fatigue syndrome; POTS, postural orthostatic tachycardia syndrome

453 Table 1. Participant demographics and pre-pandemic socioeconomic characteristics

	<b>Overall, N = 423</b>	<b>No internal tremors, N = 265</b>	<b>Has internal tremors, N = 158</b>	<b>p-value<sup>1</sup></b>
	<b>n/N, % [95% CI]</b>	<b>n/N, % [95% CI]</b>	<b>n/N, % [95% CI]</b>	
Age (years), median, IQR	46, 38-56	46, 39-58	46, 38-53	0.225
Gender				0.018
Female	313/423, 74% [69-78%]	185/265, 70% [64-75%]	128/158, 81% [74-87%]	
Male	108/423, 26% [21-30%]	78/265, 29% [24-35%]	30/158, 19% [13-26%]	
Non-binary	2/423, 0.5% [0.08-1.9%]	2/265, 0.8% [0.13-3.0%]	0/158, 0% [0.00-3.0%]	
Race and ethnicity				0.458
Asian	11/423, 2.6% [1.4-4.7%]	9/265, 3.4% [1.7-6.6%]	2/158, 1.3% [0.22-5.0%]	
Black	8/423, 1.9% [0.88-3.8%]	6/265, 2.3% [0.92-5.1%]	2/158, 1.3% [0.22-5.0%]	
Latino	15/423, 3.5% [2.1-5.9%]	7/265, 2.6% [1.2-5.6%]	8/158, 5.1% [2.4-10%]	
Multiracial or Other	21/423, 5.0% [3.2-7.6%]	13/265, 4.9% [2.7-8.4%]	8/158, 5.1% [2.4-10%]	
Non-Hispanic White	368/423, 87% [83-90%]	230/265, 87% [82-91%]	138/158, 87% [81-92%]	
Country of residence				0.807
Canada	11/423, 2.6% [1.4-4.7%]	7/265, 2.6% [1.2-5.6%]	4/158, 2.5% [0.81-6.8%]	
Germany	5/423, 1.2% [0.44-2.9%]	2/265, 0.8% [0.13-3.0%]	3/158, 1.9% [0.49-5.9%]	
United Kingdom	5/423, 1.2% [0.44-2.9%]	3/265, 1.1% [0.29-3.5%]	2/158, 1.3% [0.22-5.0%]	

U.S.	391/423, 92% [89-95%]	247/265, 93% [89-96%]	144/158, 91% [85-95%]	
Other countries	11/423, 2.6% [1.4-4.7%]	6/265, 2.3% [0.92-5.1%]	5/158, 3.2% [1.2-7.6%]	
Marital status				0.956
Divorced	42/398, 11% [7.8-14%]	27/253, 11% [7.3-15%]	15/145, 10% [6.1-17%]	
Married or civil union	237/398, 60% [55-64%]	151/253, 60% [53-66%]	86/145, 59% [51-67%]	
Never married	109/398, 27% [23-32%]	69/253, 27% [22-33%]	40/145, 28% [21-36%]	
Separated	6/398, 1.5% [0.61-3.4%]	3/253, 1.2% [0.31-3.7%]	3/145, 2.1% [0.54-6.4%]	
Widowed	4/398, 1.0% [0.32-2.7%]	3/253, 1.2% [0.31-3.7%]	1/145, 0.7% [0.04-4.4%]	
Missing data	25	12	13	
Employed pre-pandemic	338/396, 85% [81-89%]	213/252, 85% [79-89%]	125/144, 87% [80-92%]	0.537
Missing data	27	13	14	
Pre-pandemic annual household income				0.677
\$10,000 to \$35,000	20/396, 5.1% [3.2-7.8%]	12/252, 4.8% [2.6-8.4%]	8/144, 5.6% [2.6-11%]	
\$35,000 to less than \$50,000	29/396, 7.3% [5.0-10%]	15/252, 6.0% [3.5-9.8%]	14/144, 9.7% [5.6-16%]	
\$50,000 to less than \$75,000	38/396, 9.6% [7.0-13%]	25/252, 9.9% [6.6-14%]	13/144, 9.0% [5.1-15%]	
\$75,000 or more	274/396, 69% [64-74%]	176/252, 70% [64-75%]	98/144, 68% [60-75%]	
Less than \$10,000	4/396, 1.0% [0.32-2.7%]	2/252, 0.8% [0.14-3.1%]	2/144, 1.4% [0.24-5.4%]	



Prefer not to answer	31/396, 7.8% [5.5-11%]	22/252, 8.7% [5.7-13%]	9/144, 6.2% [3.1-12%]	
Missing data	27	13	14	
/ Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test				

455 Table 2. SARS-CoV-2 infection and post-COVID socioeconomic characteristics  
 456

	<b>Overall, N = 423</b>	<b>No internal tremors, N = 265</b>	<b>Has internal tremors, N = 158</b>	<b>p- value<sup>1</sup></b>
	<b>n/N, % [95% CI]</b>	<b>n/N, % [95% CI]</b>	<b>n/N, % [95% CI]</b>	
Index SARS-CoV-2 infection time period				0.006
Pre-Delta	171/373, 46% [41-51%]	97/233, 42% [35-48%]	74/140, 53% [44-61%]	
Delta	48/373, 13% [9.7-17%]	27/233, 12% [7.9-17%]	21/140, 15% [9.7-22%]	
Omicron	110/373, 29% [25-34%]	72/233, 31% [25-37%]	38/140, 27% [20-35%]	
Post-Omicron	44/373, 12% [8.8-16%]	37/233, 16% [12-21%]	7/140, 5.0% [2.2-10%]	
Missing data	50	32	18	
Hospitalized for COVID-related conditions	40/423, 9.5% [6.9-13%]	20/265, 7.5% [4.8-12%]	20/158, 13% [8.1-19%]	0.082
Number of weeks between infection and taking the symptom survey	63, 32-111	54, 26-99 [59- 71]	74, 38-118 [71- 86]	0.003
Missing data	50	32	18	
Financial difficulties caused by the pandemic				<0.001
Not at all	125/396, 32% [27-36%]	94/252, 37% [31-44%]	31/144, 22% [15-29%]	
A little	146/396, 37% [32-42%]	95/252, 38% [32-44%]	51/144, 35% [28-44%]	
Quite a bit	66/396, 17% [13-21%]	36/252, 14% [10-19%]	30/144, 21% [15-29%]	

Very much	59/396, 15% [12-19%]	27/252, 11% [7.3-15%]	32/144, 22% [16-30%]	
Missing data	27	13	14	
Do not have health insurance	15/423, 3.5% [2.1-5.9%]	9/265, 3.4% [1.7-6.6%]	6/158, 3.8% [1.6-8.5%]	0.829
Social support (someone around to help you if you need it)				0.766
Never	24/398, 6.0% [4.0-9.0%]	16/253, 6.3% [3.8-10%]	8/145, 5.5% [2.6-11%]	
Rarely	31/398, 7.8% [5.4-11%]	22/253, 8.7% [5.7-13%]	9/145, 6.2% [3.1-12%]	
Sometimes	72/398, 18% [15-22%]	42/253, 17% [12-22%]	30/145, 21% [15-28%]	
Usually	148/398, 37% [32-42%]	93/253, 37% [31-43%]	55/145, 38% [30-46%]	
Always	123/398, 31% [26-36%]	80/253, 32% [26-38%]	43/145, 30% [23-38%]	
Missing data	25	12	13	
Social isolation (how often do you feel isolated from others?)				0.039
Hardly ever or never	85/395, 22% [18-26%]	64/251, 25% [20-31%]	21/144, 15% [9.5-22%]	
Some of the time	155/395, 39% [34-44%]	94/251, 37% [32-44%]	61/144, 42% [34-51%]	
Often	155/395, 39% [34-44%]	93/251, 37% [31-43%]	62/144, 43% [35-52%]	
Missing data	28	14	14	
Housing				<0.001
I do not have a steady place to live	4/398, 1.0% [0.32-2.7%]	0/253, 0% [0.00-1.9%]	4/145, 2.8% [0.89-7.4%]	

I have a place to live today, but I am worried about losing it in the future	47/398, 12% [8.9-15%]	21/253, 8.3% [5.3-13%]	26/145, 18% [12-25%]	
I have a steady place to live	347/398, 87% [83-90%]	232/253, 92% [87-95%]	115/145, 79% [72-85%]	
Missing data	25	12	13	
<sup>l</sup> Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test				

457

458

459 Table 3. Health status

<b>Characteristic</b>	<b>Overall, N = 423</b>	<b>No internal tremors, N = 265</b>	<b>Has internal tremors, N = 158</b>	<b>p-value<sup>1</sup></b>
	<b>median, IQR</b>	<b>median, IQR</b>	<b>median, IQR</b>	
Euro-QoL visual analogue scale (0-100)	49, 32-61	50, 35-62	40, 30-60	0.007
How bad your long COVID or other symptoms are (0 to 100) on your worst days?	79, 65-86	73, 60-82	80, 73-90	<0.001
Missing data	24	11	13	
<sup>1</sup> Wilcoxon rank sum test				
IQR, interquartile range				

460